MedTrace Logo

The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry

NCT00553176 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6273

Last updated 2013-03-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term clinical, economic and humanistic outcomes of various treatment regimens, including infliximab, in Crohn's disease in real world medical practice.

Conditions

Interventions

OTHER

No intervention

At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations

Sponsors & Collaborators

  • Janssen Biotech, Inc.

    lead INDUSTRY

Principal Investigators

  • Janssen Biotech, Inc. Clinical Trial · Janssen Biotech, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-08-31
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00553176 on ClinicalTrials.gov